PDB Short entry for 1OL1 HEADER TRANSFERASE/TRANSFERASE INHIBITOR 04-AUG-03 1OL1 TITLE CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLIN A2; COMPND 9 CHAIN: B, D; COMPND 10 FRAGMENT: RESIDUES 173 - 432; COMPND 11 SYNONYM: CYCLIN A; COMPND 12 ENGINEERED: YES; COMPND 13 MOL_ID: 3; COMPND 14 MOLECULE: CIR-CIR-LEU-ILE-PFF-NH2; COMPND 15 CHAIN: F, H; COMPND 16 ENGINEERED: YES; COMPND 17 OTHER_DETAILS: CYCLIN GROOVE-BOUND PEPTIDE CIT-CIT-LEU-ILE-PFF-NH2 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 15 MOL_ID: 3; SOURCE 16 SYNTHETIC: YES; SOURCE 17 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 18 ORGANISM_TAXID: 32630 KEYWDS TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX, CELL CYCLE, KINASE-CYCLIN KEYWDS 2 COMPLEX, CYCLIN A, INHIBITOR, LIGAND EXCHANGE, DRUG DESIGN, KEYWDS 3 SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, CELL DIVISION, KEYWDS 4 MITOSIS, PHOSPHORYLATION, PEPTIDOMIMETICS EXPDTA X-RAY DIFFRACTION AUTHOR G.KONTOPIDIS,M.ANDREWS,C.MCINNES,A.COWAN,H.POWERS,L.INNES,A.PLATER, AUTHOR 2 G.GRIFFITHS,D.PATERSON,D.ZHELEVA,D.LANE,S.GREEN,M.WALKINSHAW, AUTHOR 3 P.FISCHER REVDAT 7 13-DEC-23 1OL1 1 REMARK REVDAT 6 15-NOV-23 1OL1 1 LINK ATOM REVDAT 5 15-FEB-17 1OL1 1 SOURCE JRNL REVDAT 4 13-JUL-11 1OL1 1 VERSN REVDAT 3 16-JUN-09 1OL1 1 KEYWDS JRNL REMARK SITE REVDAT 3 2 1 MASTER REVDAT 2 24-FEB-09 1OL1 1 VERSN REVDAT 1 11-DEC-03 1OL1 0 JRNL AUTH G.KONTOPIDIS,M.ANDREWS,C.MCINNES,A.COWAN,H.POWERS,L.INNES, JRNL AUTH 2 A.PLATER,G.GRIFFITHS,D.PATERSON,D.ZHELEVA,D.LANE,S.GREEN, JRNL AUTH 3 M.WALKINSHAW,P.FISCHER JRNL TITL INSIGHTS INTO CYCLIN GROOVE RECOGNITION. COMPLEX CRYSTAL JRNL TITL 2 STRUCTURES AND INHIBITOR DESIGN THROUGH LIGAND EXCHANGE JRNL REF STRUCTURE V. 11 1537 2003 JRNL REFN ISSN 0969-2126 JRNL PMID 14656438 JRNL DOI 10.1016/J.STR.2003.11.006 REMARK 2 REMARK 2 RESOLUTION. 2.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.0 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 12.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 3 NUMBER OF REFLECTIONS : 27895 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.209 REMARK 3 R VALUE (WORKING SET) : 0.206 REMARK 3 FREE R VALUE : 0.284 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1198 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.97 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1950 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2910 REMARK 3 BIN FREE R VALUE SET COUNT : 81 REMARK 3 BIN FREE R VALUE : 0.4180 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 9025 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 73 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 52.14 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.91000 REMARK 3 B22 (A**2) : 1.73000 REMARK 3 B33 (A**2) : 2.15000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.490 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.399 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 20.707 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.930 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.863 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9249 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 8494 ; 0.002 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12555 ; 1.419 ; 1.980 REMARK 3 BOND ANGLES OTHERS (DEGREES): 19820 ; 1.160 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1104 ;11.417 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1424 ; 0.101 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 9990 ; 0.013 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 1806 ; 0.007 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 3024 ; 0.331 ; 0.300 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 11318 ; 0.331 ; 0.300 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): 5588 ; 0.100 ; 0.500 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 557 ; 0.305 ; 0.500 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 40 ; 0.283 ; 0.300 REMARK 3 SYMMETRY VDW OTHERS (A): 70 ; 0.337 ; 0.300 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 9 ; 0.507 ; 0.500 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5553 ; 4.393 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9031 ; 6.910 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3696 ; 9.552 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3524 ;14.098 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BULK SOLVENT REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 1OL1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 04-AUG-03. REMARK 100 THE DEPOSITION ID IS D_1290013238. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-NOV-02 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.80 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29357 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.900 REMARK 200 RESOLUTION RANGE LOW (A) : 15.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 200 DATA REDUNDANCY : 22.50 REMARK 200 R MERGE (I) : 0.12000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 2.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.9 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.46100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: PDB ENTRY 1FIN REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 22% PEG 3350, 0.1M NA3-CIT, PH 7.80 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.24900 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 77.24100 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 56.73550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 77.24100 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.24900 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 56.73550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4700 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23570 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4780 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23490 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -5.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, H REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 FUNCTION: INVOLVED IN THE CONTROL OF THE CELL CYCLE. REMARK 400 ACTIVITY OF CDK2 IS MAXIMAL DURING S PHASE AND G2. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O TYR B 318 N LEU B 320 1.76 REMARK 500 OD2 ASP D 216 OG SER D 408 2.05 REMARK 500 O THR B 282 OG1 THR B 285 2.11 REMARK 500 O ILE C 49 OG SER C 53 2.15 REMARK 500 NZ LYS C 278 OD2 ASP D 181 2.15 REMARK 500 O SER D 416 N HIS D 419 2.17 REMARK 500 OH TYR D 225 OE1 GLU D 277 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 NZ LYS A 89 OH TYR B 280 4455 2.06 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 92 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES REMARK 500 ASP A 235 CB - CG - OD2 ANGL. DEV. = 6.3 DEGREES REMARK 500 ASP A 256 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES REMARK 500 ASP A 288 CB - CG - OD2 ANGL. DEV. = 7.2 DEGREES REMARK 500 ASP B 177 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP B 284 CB - CG - OD2 ANGL. DEV. = 6.3 DEGREES REMARK 500 ASP B 345 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP C 223 CB - CG - OD2 ANGL. DEV. = 6.3 DEGREES REMARK 500 ASP C 256 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP C 258 CB - CG - OD2 ANGL. DEV. = 7.5 DEGREES REMARK 500 ASP D 205 CB - CG - OD2 ANGL. DEV. = 6.5 DEGREES REMARK 500 ASP D 216 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP D 284 CB - CG - OD2 ANGL. DEV. = 5.9 DEGREES REMARK 500 ASP D 345 CB - CG - OD2 ANGL. DEV. = 6.0 DEGREES REMARK 500 ASP D 393 CB - CG - OD2 ANGL. DEV. = 5.4 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 12 -172.26 166.10 REMARK 500 THR A 14 172.25 -50.21 REMARK 500 TYR A 15 -81.68 50.94 REMARK 500 VAL A 17 129.20 11.68 REMARK 500 LEU A 37 124.27 96.64 REMARK 500 THR A 41 43.86 -146.72 REMARK 500 GLU A 42 -56.92 179.19 REMARK 500 HIS A 60 142.99 -172.64 REMARK 500 GLN A 85 -177.54 -175.99 REMARK 500 LEU A 96 -56.40 111.31 REMARK 500 ARG A 122 58.16 36.01 REMARK 500 ARG A 126 -0.63 68.37 REMARK 500 ASP A 127 46.71 -150.41 REMARK 500 LYS A 129 146.36 -178.58 REMARK 500 ASP A 145 80.76 59.17 REMARK 500 PHE A 152 54.84 -118.12 REMARK 500 THR A 160 -79.03 -0.14 REMARK 500 THR A 165 160.77 139.88 REMARK 500 ARG A 199 -6.67 75.11 REMARK 500 SER A 207 153.70 172.30 REMARK 500 TRP A 227 78.42 -166.22 REMARK 500 PRO A 284 -35.73 -35.41 REMARK 500 THR A 290 -165.55 -112.17 REMARK 500 PRO B 176 51.17 -53.93 REMARK 500 HIS B 179 -101.15 -57.49 REMARK 500 GLU B 180 -65.66 -0.75 REMARK 500 ASP B 283 65.43 69.95 REMARK 500 ASP B 284 49.41 33.54 REMARK 500 TYR B 318 -115.64 -59.28 REMARK 500 PHE B 319 -39.05 39.55 REMARK 500 ALA B 325 155.95 -43.50 REMARK 500 ASN B 326 124.57 -178.06 REMARK 500 TRP B 372 104.00 -16.69 REMARK 500 GLN B 407 -2.48 -142.47 REMARK 500 LEU B 424 147.44 -37.06 REMARK 500 VAL C 7 -66.13 -96.37 REMARK 500 TYR C 15 -78.75 -120.05 REMARK 500 THR C 39 27.44 -64.21 REMARK 500 THR C 41 -108.88 -81.90 REMARK 500 GLU C 42 15.70 -150.01 REMARK 500 LEU C 96 -22.98 67.56 REMARK 500 ARG C 126 0.27 81.19 REMARK 500 ASP C 127 47.29 -155.07 REMARK 500 ASP C 145 68.99 66.17 REMARK 500 HIS C 161 -134.70 69.80 REMARK 500 GLU C 162 121.29 62.20 REMARK 500 VAL C 163 -103.73 61.11 REMARK 500 VAL C 164 -112.15 48.89 REMARK 500 THR C 165 -69.82 -157.24 REMARK 500 LEU C 166 -73.48 96.74 REMARK 500 REMARK 500 THIS ENTRY HAS 74 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 VAL A 163 VAL A 164 -145.00 REMARK 500 PRO B 346 TYR B 347 -149.28 REMARK 500 LYS D 202 GLN D 203 146.04 REMARK 500 LEU D 227 GLN D 228 144.97 REMARK 500 ALA D 344 ASP D 345 -146.42 REMARK 500 ASP D 345 PRO D 346 149.23 REMARK 500 PRO D 346 TYR D 347 -145.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN F OF CIR-CIR-LEU-ILE-PFF REMARK 800 -NH2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN H OF CIR-CIR-LEU-ILE-PFF REMARK 800 -NH2 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H06 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0U RELATED DB: PDB REMARK 900 M. SMEGMATIS ARYLAMINE N-ACETYL TRANSFERASE REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H- INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{ 4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2- DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3- THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO -2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6- AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN- DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN- DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN- DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKU RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU -ILE-(P- REMARK 900 F-PHE)-NH2 REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL -PHE)- REMARK 900 NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F- PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/ REMARK 900 CYCLIN A REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX DBREF 1OL1 A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1OL1 B 173 432 UNP P20248 CG2A_HUMAN 173 432 DBREF 1OL1 C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1OL1 D 173 432 UNP P20248 CG2A_HUMAN 173 432 DBREF 1OL1 F 500 505 PDB 1OL1 1OL1 500 505 DBREF 1OL1 H 500 505 PDB 1OL1 1OL1 500 505 SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 F 6 CIR CIR LEU ILE PFF NH2 SEQRES 1 H 6 CIR CIR LEU ILE PFF NH2 MODRES 1OL1 CIR F 500 ARG CITRULLINE MODRES 1OL1 CIR F 501 ARG CITRULLINE MODRES 1OL1 PFF F 504 PHE 4-FLUORO-L-PHENYLALANINE MODRES 1OL1 CIR H 500 ARG CITRULLINE MODRES 1OL1 CIR H 501 ARG CITRULLINE MODRES 1OL1 PFF H 504 PHE 4-FLUORO-L-PHENYLALANINE HET CIR F 500 11 HET CIR F 501 11 HET PFF F 504 12 HET NH2 F 505 1 HET CIR H 500 11 HET CIR H 501 11 HET PFF H 504 12 HET NH2 H 505 1 HETNAM CIR CITRULLINE HETNAM PFF 4-FLUORO-L-PHENYLALANINE HETNAM NH2 AMINO GROUP FORMUL 5 CIR 4(C6 H13 N3 O3) FORMUL 5 PFF 2(C9 H10 F N O2) FORMUL 5 NH2 2(H2 N) FORMUL 7 HOH *73(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 ALA A 95 1 9 HELIX 3 3 PRO A 100 SER A 120 1 21 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 SER A 181 ARG A 199 1 19 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 ASP A 270 ARG A 274 5 5 HELIX 12 12 SER A 276 HIS A 283 1 8 HELIX 13 13 PRO A 284 GLN A 287 5 4 HELIX 14 14 TYR B 178 CYS B 193 1 16 HELIX 15 15 THR B 207 TYR B 225 1 19 HELIX 16 16 GLN B 228 LEU B 243 1 16 HELIX 17 17 LYS B 252 GLU B 269 1 18 HELIX 18 18 GLU B 274 ILE B 281 1 8 HELIX 19 19 THR B 287 LEU B 302 1 16 HELIX 20 20 THR B 310 TYR B 318 1 9 HELIX 21 21 ASN B 326 ASP B 343 1 18 HELIX 22 22 ASP B 343 LEU B 348 1 6 HELIX 23 23 LEU B 351 THR B 368 1 18 HELIX 24 24 GLU B 374 THR B 380 1 7 HELIX 25 25 THR B 383 LYS B 400 1 18 HELIX 26 26 ALA B 401 HIS B 404 5 4 HELIX 27 27 GLN B 407 TYR B 413 1 7 HELIX 28 28 ASN B 415 HIS B 419 5 5 HELIX 29 29 GLY B 420 LEU B 424 5 5 HELIX 30 30 PRO C 45 LYS C 56 1 12 HELIX 31 31 LEU C 87 ALA C 93 1 7 HELIX 32 32 PRO C 100 SER C 120 1 21 HELIX 33 33 ALA C 170 LEU C 175 1 6 HELIX 34 34 THR C 182 ARG C 199 1 18 HELIX 35 35 SER C 207 GLY C 220 1 14 HELIX 36 36 GLY C 229 MET C 233 5 5 HELIX 37 37 ASP C 247 VAL C 252 1 6 HELIX 38 38 ASP C 256 LEU C 267 1 12 HELIX 39 39 SER C 276 ALA C 282 1 7 HELIX 40 40 HIS C 283 GLN C 287 5 5 HELIX 41 41 TYR D 178 GLU D 190 1 13 HELIX 42 42 THR D 207 TYR D 225 1 19 HELIX 43 43 GLN D 228 SER D 244 1 17 HELIX 44 44 LEU D 249 GLU D 269 1 21 HELIX 45 45 GLU D 274 ILE D 281 1 8 HELIX 46 46 THR D 287 LEU D 302 1 16 HELIX 47 47 THR D 310 PHE D 319 1 10 HELIX 48 48 LEU D 320 GLN D 322 5 3 HELIX 49 49 ASN D 326 ASP D 343 1 18 HELIX 50 50 ASP D 343 LEU D 348 1 6 HELIX 51 51 LEU D 351 THR D 368 1 18 HELIX 52 52 PRO D 373 GLY D 381 1 9 HELIX 53 53 LEU D 387 LYS D 400 1 14 HELIX 54 54 GLN D 407 TYR D 413 1 7 SHEET 1 AA 5 PHE A 4 LYS A 9 0 SHEET 2 AA 5 VAL A 18 ASN A 23 -1 O LYS A 20 N VAL A 7 SHEET 3 AA 5 VAL A 29 ILE A 35 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C CIR F 500 N CIR F 501 1555 1555 1.35 LINK C CIR F 501 N LEU F 502 1555 1555 1.32 LINK C ILE F 503 N PFF F 504 1555 1555 1.33 LINK C PFF F 504 N NH2 F 505 1555 1555 1.34 LINK C CIR H 500 N CIR H 501 1555 1555 1.33 LINK C CIR H 501 N LEU H 502 1555 1555 1.34 LINK C ILE H 503 N PFF H 504 1555 1555 1.34 LINK C PFF H 504 N NH2 H 505 1555 1555 1.33 CISPEP 1 GLN B 323 PRO B 324 0 -8.08 CISPEP 2 GLN D 323 PRO D 324 0 -6.43 SITE 1 AC1 13 GLU A 12 GLY A 13 VAL A 163 THR A 165 SITE 2 AC1 13 MET B 210 LEU B 214 TRP B 217 ARG B 250 SITE 3 AC1 13 GLN B 254 TYR B 271 ILE B 281 ASP B 283 SITE 4 AC1 13 THR B 285 SITE 1 AC2 10 ASP C 247 MET D 210 LEU D 214 TRP D 217 SITE 2 AC2 10 ARG D 250 GLN D 254 ILE D 281 THR D 282 SITE 3 AC2 10 ASP D 283 THR D 285 CRYST1 74.498 113.471 154.482 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013423 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008813 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006473 0.00000